Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doravirine/Lamivudine/TDF vs ATRIPLA in Treatment-Naïve HIV-1
NCT02403674Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Jun 2015; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02403674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403674.